An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment.

Autor:	Arishi NA; Department of Pharmacy, Qassim Armed Forces Hospital, Buraydah, SAU., Althomali NM; Department of Pharmacy, King Faisal Specialist Hospital and Research Center, Jeddah, SAU., Dighriri IM; Department of Pharmacy, King Abdulaziz Specialist Hospital, Taif, SAU., Alharthi MS; Department of Pharmacy, King Abdulaziz Specialist Hospital, Taif, SAU., Alqurashi GB; Department of Pharmacy, Taif University, Taif, SAU., Musharraf RA; Department of Pharmacy, King Salman Bin Abdulaziz Medical City, Medina, SAU., Albuhayri AH; Department of Pharmacy, University of Tabuk, Tabuk, SAU., Almalki MK; Medical School, Alrayan Medical College, Medina, SAU., Alnami SA; Department of Pharmacy, Al-Emis Hospital, Jazan, SAU., Mashraqi ZO; Department of Pharmacy, Al Nahdi Medical Company, Jazan, SAU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Jan 24; Vol. 15 (1), pp. e34158. Date of Electronic Publication: 2023 Jan 24 (Print Publication: 2023).
DOI:	10.7759/cureus.34158
Abstrakt:	Fluvoxamine (FLV) is a well-tolerated, widely accessible antidepressant of the selective serotonin reuptake inhibitor (SSRI) category. It was formerly used to reduce anxiety, obsessive-compulsive disorder, panic attacks, and depression. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enclosed ribonucleic acid (RNA) virus with a positive-sense RNA genome that belongs to the Coronaviridae family. Infection with SARS-CoV-2 causes clinical deterioration, increased hospitalization, morbidity, and death. As a result, the purpose of this research was to review FLV and its use in the treatment of SARS-CoV-2. FLV is a potent sigma-1 receptor (S1R) agonist that modulates inflammation by reducing mast cell downregulation, cytokine production, platelet aggregation, interfering with endolysosomal viral transport, and delaying clinical deterioration. FLV treatment reduced the requirement for hospitalization in high-risk outpatients with early identified coronavirus disease 2019 (COVID-19), defined by detention in a COVID-19 emergency department or transfer to a tertiary hospital. In addition, FLV may reduce mortality and risk of hospital admission or death in patients with SARS-CoV-2. The most common adverse effect is nausea; other gastrointestinal symptoms, neurologic consequences, and suicidal thoughts may also occur. There is no evidence that FLV can treat children with SARS-CoV-2. Although FLV is not expected to increase the frequency of congenital abnormalities during pregnancy, this risk must be balanced with the potential benefit. More research is required to determine the effectiveness, dose, and mechanisms of action of FLV; however, FLV appears to offer significant promise as a safe and widely accessible drug that can be repurposed to reduce substantial morbidity and mortality due to SARS-CoV-2. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Arishi et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu